ArticlePloS one2011
Securinine, a myeloid differentiation agent with therapeutic potential for AML.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 57 citations in OpenAlex.
- Reawakening Differentiation Therapy in Acute Myeloid Leukemia: A Comprehensive Review of ATRA-Based Combination Strategies.Current oncology (Toronto, Ont.) · 2026Review
- Norchelerythrine fromInternational journal of oncology · 2025Article
- Advances in the Total Synthesis of Pharmacologically Important Fused Indolizidine Alkaloids: Securinine, Gephyrotoxin and Lepadiformine.Current organic synthesis · 2025Review
- Naringenin prevents non-alcoholic steatohepatitis by modulating the host metabolome and intestinal microbiome in MCD diet-fed mice.Food science & nutrition · 2023Article
- Phytochemicals and bioactive compounds effective against acute myeloid leukemia: A systematic review.Food science & nutrition · 2023Article
- Anti-leukemic principle(s) fromCytotechnology · 2022Article
- Research Progress of Natural Small-Molecule Compounds Related to Tumor Differentiation.Molecules (Basel, Switzerland) · 2022Review
- Unique indolizidine alkaloid securinine is a promising scaffold for the development of neuroprotective and antitumor drugs.RSC advances · 2021Review
- L-securinine inhibits the proliferation of A549 lung cancer cells and promotes DKK1 promoter methylation.Oncology letters · 2017Article
- ZNF521 sustains the differentiation block in MLL-rearranged acute myeloid leukemia.Oncotarget · 2017Article
- GSK-3 Inhibition Sensitizes Acute Myeloid Leukemia Cells to 1,25D-Mediated Differentiation.Cancer research · 2016Article
- Synthesis and Antiproliferative and Metabolic Evaluations of Novel Securinine Derivatives.ACS medicinal chemistry letters · 2016Article
- Securinine from Phyllanthus glaucus Induces Cell Cycle Arrest and Apoptosis in Human Cervical Cancer HeLa Cells.PloS one · 2016Article
- Production of therapeutically relevant indolizidine alkaloids in Securinega suffruticosa in vitro shoots maintained in liquid culture systems.Applied biochemistry and biotechnology · 2015Article
- The interplay of autophagy and β-Catenin signaling regulates differentiation in acute myeloid leukemia.Cell death discovery · 2015Article
- Retinoic acid synergizes ATO-mediated cytotoxicity by precluding Nrf2 activity in AML cells.British journal of cancer · 2014Article
- Nitric oxide mediates selective degeneration of hypothalamic orexin neurons through dysfunction of protein disulfide isomerase.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2013Article
- GSK3 is a regulator of RAR-mediated differentiation.Leukemia · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
Abstract
As the defining feature of Acute Myeloid Leukemia (AML) is a maturation arrest, a highly desirable therapeutic strategy is to induce leukemic cell maturation. This therapeutic strategy has the potential of avoiding the significant side effects that occur with the traditional AML therapeutics. We identified a natural compound securinine, as a leukemia differentiation-inducing agent. Securinine is a plant-derived alkaloid that has previously been used clinically as a therapeutic for primarily neurological related diseases. Securinine induces monocytic differentiation of a wide range of myeloid leukemia cell lines as well as primary leukemic patient samples. Securinine's clinical potential for AML can be seen from its ability to induce significant growth arrest in cell lines and patient samples as well as its activity in significantly impairing the growth of AML tumors in nude mice. In addition, securinine can synergize with currently employed agents such as ATRA and decitabine to induce differentiation. This study has revealed securinine induces differentiation through the activation of DNA damage signaling. Securinine is a promising new monocytic differentiation inducing agent for AML that has seen previous clinical use for non-related disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.